Beryl Drugs Limited Declares Non-Large Entity Status Under SEBI Regulations
Beryl Drugs Limited has declared to BSE Limited that it does not qualify as a Large Entity or Large Corporate under SEBI regulations as on March 31, 2026. The declaration, submitted on April 6, 2026, complies with SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 and BSE Circular LIST/COMP/05/2019-20. Managing Director Sanjay Sethi authorized the regulatory filing, confirming the company's non-large entity status under applicable regulatory frameworks.
*this image is generated using AI for illustrative purposes only.
Beryl Drugs Limited has submitted a regulatory declaration to BSE Limited confirming its status regarding Large Entity classification under Securities and Exchange Board of India (SEBI) regulations. The pharmaceutical company made this disclosure as part of its ongoing compliance obligations with stock exchange requirements.
Regulatory Compliance Declaration
The company filed its declaration on April 6, 2026, addressing the requirements outlined in SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. This circular, read in conjunction with BSE Circular No. LIST/COMP/05/2019-20 dated April 11, 2019, mandates listed companies to declare their status regarding Large Entity or Large Corporate classification.
| Parameter: | Details |
|---|---|
| Declaration Date: | April 6, 2026 |
| Assessment Date: | March 31, 2026 |
| SEBI Circular Reference: | SEBI/HO/DDHS/CIR/P/2018/144 |
| BSE Circular Reference: | LIST/COMP/05/2019-20 |
| Script Code: | 524606 |
Company Status Confirmation
Beryl Drugs Limited confirmed that it does not qualify as a Large Entity or Large Corporate as defined under clause 2.2 of the SEBI circular as on March 31, 2026. This classification has implications for various regulatory requirements and compliance obligations that apply differently to large entities versus smaller companies.
Management Authorization
The declaration was signed by Sanjay Sethi, Managing Director of Beryl Drugs Limited, who holds Director Identification Number (DIN) 00090277. The document was submitted to BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai, as part of the company's regulatory filing obligations.
Company Information
Beryl Drugs Limited operates from its registered office located at Ground Floor, 133, Kanchan Bagh, Indore - 452001, Madhya Pradesh. The company maintains its corporate identification number as L02423MP1993PLC007840, reflecting its incorporation status and business classification within the pharmaceutical sector.
Historical Stock Returns for Beryl Drugs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -4.95% | -12.32% | +5.24% | -6.52% | -6.40% | +295.95% |
What growth trajectory would Beryl Drugs need to achieve to potentially qualify as a Large Entity in future assessment periods?
How might Beryl Drugs' non-Large Entity status affect its ability to compete for major pharmaceutical contracts or partnerships?
Will the company's current classification limit its access to certain capital markets or institutional investor categories?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
